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Abstract 
Acute myeloid leukemia (AML) with t(6;9)(p23;q34) is well known to have a poor 
prognosis treated with chemotherapy and autotransplantation. The presence of this 
karyotype is an indicator for allogeneic hematopoietic stem cell transplantation (HSCT); 
however, the impact of t(6;9)(p23;q34) on the HSCT outcome remains unclear. We 
conducted a matched-pair analysis of de novo AML patients with and without 
t(6;9)(p23;q34) using data obtained from the Japanese HSCT data registry. Fifty-seven 
patients with t(6;9)(p23;q34) received transplants between 1996 and 2007, and 171 of 
2056 normal karyotype patients matched for age, disease status at HSCT and graft 
source were selected. The overall survival, disease-free survival, cumulative incidence 
of relapse and the non-relapse mortality in t(6;9)(p23;q34) patients were comparable to 
those for normal karyotype patients. A univariate analysis showed that t(6;9)(p23;q34) 
had no significant impact on the overall survival. These findings suggest that allogeneic 
HSCT may overcome the unfavorable impact of t(6;9)(p23;q34) as an independent 
prognostic factor. 
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Introduction 
Acute myeloid leukemia (AML) is a hematological malignancy resulting from the 
proliferation of leukemic stem cells. Because of the resistance of leukemic stem cells to 
chemotherapy,(1) long-term survival is generally seen in only 50% of patients treated 
with chemotherapy alone. Therefore, allogeneic stem cell transplantation (HSCT) is 
often considered as a curative treatment option.(2) AML is the most common indication 
for HSCT in North America and in Japan, but fatal transplant-related adverse events are 
difficult to avoid, despite the improvements in supportive treatment in recent years. 
Therefore, treatment of AML is hard to standardize, and the attending physician must 
make a decision on a case-by-case basis, weighing the advantages and disadvantage of 
HSCT. 
 The results of past large clinical trials have indicated that abnormalities of the 
chromosomal karyotype are considered to be one of the most powerful factors to predict 
the patient prognosis.(3, 4) AML with unfavorable cytogenetic risk group, such as a 
partial deletion of the long arm of chromosome 7 (del (7q)), monosomy of chromosome 
7 (-7) or with a complex karyotype is considered to be a good indication for HSCT, 
even during the first remission, because of the high cytogenetic risk associated with 
chemotherapy and the beneficial outcome that can be achieved by HSCT.(5-8) 
 The translocation of chromosome (6;9)(p23;q34) forming the DEK/NUP214 
fusion mRNA is observed in approximately 1% of AML cases.(9) The characteristics of 
AML with t(6;9)(p23;q34) are known to include development at a younger age,(10) 
resistance to chemotherapy, and a very poor prognosis.(9) Therefore, the presence of 
this karyotype in AML patients is an indication for HSCT; however, the impact of 
t(6;9)(p23;q34) on the outcome of HSCT remains unclear because of the rarity of this 
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entity. We conducted a retrospective study to examine the outcomes of HSCT in AML 
patients with t(6;9)(p23;q34) using the data from the Japan Society for Hematopoietic 
Cell Transplantation Data Registry. 
 
Patients and methods 
Study population 
Clinical data were collected from the databases of the Japan Society for Hematopoietic 
Cell Transplantation (JSHCT) and the Japan Cord Blood Bank Network (JCBBN) using 
a standardized report form. Follow-up reports were submitted at 100 days, 1 year and 
annually after HSCT. Patients with de novo AML aged 15 years or older at the time of 
first HSCT and who received the transplant between January 1996 and December 2007 
were extracted from the databases. We compared the clinical features and the outcomes 
among the patients with t(6;9)(p23;q34) and the patients with a normal karyotype in 
G-band staining. Cytogenetic data were analyzed according to the Southwestern 
Oncology Group (SWOG) criteria in each institution(7) instead of by central review. 
We selected patient pairs with t(6;9)(p23;q34) and the normal karyotype using an 
optimal matching method with the following 3 matching factors: recipient age, disease 
status at HSCT and graft source. This study was approved by the Committee for 
Nationwide Survey Data Management of the Japan Society for Hematopoietic Cell 
Transplantation. Written informed consent was obtained in accordance with the 
Declaration of Helsinki. 
 
Statistical analysis 
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The overall survival (OS) was defined as the number of days from HSCT until death 
from any cause. Disease relapse was defined as the number of days from HSCT to 
relapse of the underlying disease. Non-relapse mortality (NRM) was defined as death 
without relapse. Any patients who were alive at the last-follow-up date were censored. 
All statistical analyses were performed using the R version 2.13.0 software program (R 
Foundation for Statistical Computing; www.r-project.org). Probabilities and 
times-to-events were compared between the two groups using the Mantel-Haenszel 
method and stratified Cox proportional hazard modeling, respectively. The cumulative 
incidences of NRM and relapse were calculated considering each other event as a 
competing risk, and were compared using the stratified Grey test.(11) P values were two 




A total of 2577 AML cases met the inclusion criteria. The number of cases with 
t(6;9)(p23;q34) and a normal karyotype was 57 and 2,056, respectively; and 171 
patients with the normal karyotype were selected for matched-pair analysis by a 1:3 
matching ratio. The characteristics of the patients are shown in Table 1; there were no 
statistically significant differences between the t(6;9)(p23;q34) patients and the normal 
karyotype patients except the use of total body irradiation (TBI) as a preconditioning 
regimen. 
 
Survival, relapse and non-relapse mortality 
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The probability of OS in the patients with t(6;9)(p23;q34) was as good as that for 
patients with a normal karyotype (the probability of 5-year OS in t(6;9)(p23;q34) and 
normal karyotype patients was 45% and 40%, respectively; Figure 1A). When the 
t(6;9)(p23;q34) patients and the normal karyotype patients were further categorized 
according to the disease status at HSCT, the OS of the t(6;9)(p23;q34) patients and the 
normal karyotype patients were comparable in both the CR at HSCT patients, and the 
non-CR at HSCT patients (Figure 1B). The probability of DFS in these patients was 
also not significantly different (the probability of 5-year DFS in patients with 
t(6;9)(p23;q34) and the normal karyotype was 42% and 33%, respectively; Figure 1C). 
The cumulative incidence of relapse (Figure 2A) and the NRM (Figure 2B) in 
t(6;9)(p23;q34) patients were also comparable to those for normal karyotype patients 
(the 5-year cumulative incidence was 42% in t(6;9)(p23;q34) patients and 45% in 
normal karyotype patients for relapse (P=0.34) and 16% and 22% (P=0.85) for NRM). 
The prognostic factors affecting OS revealed that there were no significant differences 
related to karyotype, gender, gender mismatch between donor and recipient, HLA 
disparity, recipient cytomegalovirus serostatus and use of TBI for the preconditioning 
regimen by the univariate analyses (Table 2A). 
 
Discussion 
Previous reports have confirmed the negative impact of t(6;9)(p23;q34) on the outcome 
after standard-dose chemotherapy and high-dose therapy with autologous stem cell 
transplantation in patients with AML.(9, 10) The current matched-pair analysis of the 
nationwide survey demonstrated that the OS and the TRM, as well as the relapse rate, 
were independent of the presence of t(6;9)(p23;q34) in allogeneic HSCT recipients, thus 
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suggesting that allogeneic HSCT may be able to overcome the unfavorable effect of 
t(6;9)(p23;q34) in AML patients.  
 However, it is difficult to draw any firm conclusions regarding the results of 
the present analysis owing to the small numbers of patients in the matched-pairs subsets. 
These findings require confirmation in larger studies specifically examining the impact 
of t(6;9)(p23;q34) status. Nevertheless, the suggestion that allogeneic HSCT appears to 
overcome the adverse survival impact of t(6;9)(p23;q34) is supported by other 
studies.(12, 13) In a EBMT study of AML patients with t(6;9)(p23;q34), allogeneic 
HSCT produced responses that were independent of t(6;9)(p23;q34), and the 3-year OS 
of patients with t(6;9)(p23;q34) was as high as 51±7%, comparable to AML patients 
with the normal karyotype.(13) Also, the incidence of relapse following allogeneic 
HSCT appeared to be similar in patients with t(6;9)(p23;q34) compared to those without 
t(6;9)(p23;q34). However, the EBMT study made it somewhat difficult to determine 
whether HSCT would lead to a good outcome, because 87% of the patients were 
transplanted while in CR, while only 29 of 57 (51%) patients in our study received 
HSCT in CR, which is a more clinically relevant expectation, as a CR is difficult to 
achieve in these patients.  
 In conclusion, the current study showed that AML patients with 
t(6;9)(p23;q34) can be expected to have a post-transplant survival comparable to 
patients with a normal karyotype, thereby supporting the opinion that they are good 
candidates for HSCT. 
  
Acknowledgements 
The authors are indebted to all of the patients and the staff of the participating 
 9 / 12 
 
institutions of the Japan Society for Hematopoietic Cell Transplantation, the Japan 
Marrow Donor Program, The Japanese Cord Blood Bank Network and The Japanese 
Society of Pediatric Hematology. The authors would like to thank Ms. Takako Sakai, 
data manager of the Japan Society for Hematopoietic Cell Transplantation Data Registry, 
for their excellent assistance. 
 
Conflict of Interest 
The authors declare no competing financial interests. 
 
References 
1. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. 
Chemotherapy-resistant human AML stem cells home to and engraft within the 
bone-marrow endosteal region. Nat Biotechnol 2007 Nov; 25(11): 1315-1321. 
 
2. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. 
Autologous or allogeneic bone marrow transplantation compared with intensive 
chemotherapy in acute myelogenous leukemia. European Organization for 
Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie 
Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. 
N Engl J Med 1995 Jan 26; 332(4): 217-223. 
 
3. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic 
stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia 
 10 / 12 
 
in first disease remission: a metaanalysis. Cancer 2005 Apr 15; 103(8): 
1652-1658. 
 
4. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, et al. Allogeneic 
compared with autologous stem cell transplantation in the treatment of patients 
younger than 46 years with acute myeloid leukemia (AML) in first complete 
remission (CR1): an intention-to-treat analysis of the 
EORTC/GIMEMAAML-10 trial. Blood 2003 Aug 15; 102(4): 1232-1240. 
 
5. Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Kanamori H, Usuki K, et al. 
A Markov decision analysis of allogeneic hematopoietic cell transplantation 
versus chemotherapy in patients with acute myeloid leukemia in first remission. 
Blood  Feb 17; 117(7): 2113-2120. 
 
6. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. 
The importance of diagnostic cytogenetics on outcome in AML: analysis of 
1,612 patients entered into the MRC AML 10 trial. The Medical Research 
Council Adult and Children's Leukaemia Working Parties. Blood 1998 Oct 1; 
92(7): 2322-2333. 
 
7. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, 
et al. Karyotypic analysis predicts outcome of preremission and postremission 
therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern 
Cooperative Oncology Group Study. Blood 2000 Dec 15; 96(13): 4075-4083. 
 11 / 12 
 
 
8. van der Straaten HM, van Biezen A, Brand R, Schattenberg AV, Egeler RM, 
Barge RM, et al. Allogeneic stem cell transplantation for patients with acute 
myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 
7 abnormalities. Haematologica 2005 Oct; 90(10): 1339-1345. 
 
9. Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson 
RA, et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML 
emphasizes the need for a prospective, multicenter initiative for rare 'poor 
prognosis' myeloid malignancies. Leukemia 2006 Jul; 20(7): 1295-1297. 
 
10. Garcon L, Libura M, Delabesse E, Valensi F, Asnafi V, Berger C, et al. 
DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic 
stratification. Leukemia 2005 Aug; 19(8): 1338-1344. 
 
11. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure 
probabilities in the presence of competing risks: new representations of old 
estimators. Stat Med 1999 Mar 30; 18(6): 695-706. 
 
12. Gupta M, Ashok Kumar J, Sitaram U, Neeraj S, Nancy A, Balasubramanian P, 
et al. The t(6;9)(p22;q34) in myeloid neoplasms: a retrospective study of 16 
cases. Cancer Genet Cytogenet  Dec; 203(2): 297-302. 
 
 12 / 12 
 
13. Esteve J, Labopin M, Socie G, Ljungman PT, Maertens J, Schattenberg AV, et 
al. Allogeneic hematopoietic stem-cell transplantation in early phase might 
overcome the adverse prognosis of acute myeloid leukemia with translocation 
t(6;9)(p23;q34)/DEK-NUP214(CAN) rearrangement. a retrospective analysis 




Figure 1. Survival of the patients. A. The overall survival (OS) of the patients stratified 
by cytogenetics. B. The OS of the patients grouped according to their disease status at 
transplantation. C. The disease-free survival of the patients. 
 
Figure 2. Cumulative incidence of events after transplantation stratified by cytogenetics. 
A. The cumulative incidence of relapse of the patients. B. The cumulative incidence of 






Table 1. Patient characteristics
t(6;9)(p23;q34) Normalkaryotype p value
Age






Male 34 97 0.758
Female 23 74
CR1 or CR2 29 87 1.0
Not in remission 28 84
No 21 33 0.0102
Yes 33 131
Donor
Related 26 78 1.0
Unrelated bone marrow 18 54
Unrelated cord blood 13 39




Abbreviations: CR, complete remission; HSCT, hematopoietic stem cell transplantation;
TBI, total body irradiation.
Preconditioning regimen, TBI
Number of HLA mismatch
Disease status at HSCT
Table 2. Prognostic factors affecting overall survival
Risk factor Hazard ratio 95%CI p value
Karyotype t(6;9) 1.07 0.66-1.74 0.79
Gender Male 1.06 0.64-1.73  0.83
Gender mismatch Female to Male 1.41 0.74-2.68  0.29
HLA compatibility mismatch 0.98 0.57-1.75  0.94
Recipient CMV Positive 0.27 0.028-2.70  0.27
Donor CMV Positive 1.51 0.61-3.78  0.37
TBI Yes 1.47 0.75-2.90  0.26
Abbreviations: CMV, cytomegalovirus; TBI, total body irradiation.
